Table 2

Crude and adjusted associations of microvascular complications with 1-year outcomes

Composite outcomeAll-cause mortalityHF hospitalizations
No. at riskNo. of events (%)No. at riskNo. of events (%)No. at riskNo. of events (%)
DM without microvascular complications (referent for HR)2,024437 (21.6)2,024209 (10.3)2,024271 (13.4)
DM with microvascular complications543172 (31.7)54376 (14.0)543114 (21.0)
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Univariable1.55 (1.32–1.94)<0.0011.39 (1.07–1.81)0.0141.63 (1.31–2.02)<0.001
Model 11.60 (1.34–1.92)<0.0011.42 (1.08–1.88)0.0121.59 (1.24–2.04)<0.001
Model 21.52 (1.25–1.86)<0.0011.43 (1.07–1.91)0.0151.46 (1.13–1.90)0.004
Model 31.34 (1.06–1.69)0.0151.12 (0.78–1.60)0.5361.43 (1.06–1.93)0.019
Model 41.35 (1.04–1.76)0.0241.16 (0.78–1.73)0.4561.49 (1.06–2.09)0.020
  • Model 1: age, sex, ethnicity, NYHA class, HF subtype (HFrEF/HFpEF), duration of HF. Model 2: model 1 + BMI, history of hypertension, atrial fibrillation, CAD, usage of insulins, and oral DM drugs. Model 3: model 2 + usage of ACEi/ARB, β-blockers, mineralocorticoid receptor antagonist, creatinine levels, hemoglobin levels, type of DM. Model 4: model 3 + duration of DM.